

**APPENDIX II: Clean Copy of Claims as Pending**

1. (amended) A composition for the nasal administration of a drug in a dry powder form having an average particle size of between 10 and 20 microns, in a dosage formulation suitable for administration to the nasal region,

the dry powder form comprising microparticles formed of the drug and a polymer or diketopiperazine.

2. The composition of claim 1 wherein the drug is selected from the group consisting of antihistamine, vasoconstrictors, antiinflammatories and analgesics.

3. The composition of claim 2 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.

4. The composition of claim 1 wherein the drug is formulated in a polymeric carrier.

5. The composition of claim 1 wherein the drug is formulated in a diketopiperazine formulation.

6. The composition of claim 1 wherein the dry powder formulation consists essentially of drug.

7. (amended) A drug delivery device for nasal administration comprising a drug in a dry powder form having an average particle size of between 10 and 20 microns, in a dosage formulation for administration to the nasal region, and a device for delivering a measured dose of the drug to the nasal mucosa, wherein the dry powder form comprises microparticles formed of the drug and a polymer or diketopiperazine.

8. The device of claim 7 wherein the device is a nasal insufflator.

AMENDMENT AND RESPONSE TO OFFICE ACTION

9. The device of claim 7 wherein the drug is selected from the group consisting of antihistamine, vasoconstrictors, antiinflammatories and analgesics.
10. The device of claim 7 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.
11. The device of claim 7 wherein the drug is formulated in a polymeric carrier.
12. The device of claim 7 wherein the drug is formulated in a diketopiperazine formulation.
13. The device of claim 7 wherein the dry powder formulation consists essentially of drug.
14. (amended) A method of administering a drug to the nasal region of a patient in need thereof, comprising nasally administering a dry powder form of a drug having an average particle size of between 10 and 20 microns, in a dosage formulation suitable for nasal administration,  
wherein the dry powder form comprises microparticles formed of the drug and a polymer or diketopiperazine.
15. The method of claim 14 wherein the drug is selected from the group consisting of antihistamine, vasoconstrictors, antiinflammatories and analgesics.
16. The method of claim 14 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.
17. The method of claim 14 wherein the drug is formulated in a polymeric carrier.
18. The method of claim 14 wherein the drug is formulated in a diketopiperazine formulation.

U.S.S.N.: 09/766,362

Filed: January 19, 2001

AMENDMENT AND RESPONSE TO OFFICE ACTION

19. The method of claim 14 wherein the dry powder formulation consists essentially of drug.

ATL1 #534542 v1